These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34886931)

  • 21. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia.
    Cheng X; Zhao Y; Gu H; Zhao L; Zang Y; Wang X; Wu R
    Int J Immunopathol Pharmacol; 2020; 34():2058738420934936. PubMed ID: 32720540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.
    Svensson EM; Dosne AG; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):682-691. PubMed ID: 27863179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
    Mugabo P; Mulubwa M
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):519-530. PubMed ID: 30617957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
    Yang S; Dumitrescu TP
    Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
    Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
    Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis.
    Mugabo P; Mulubwa M
    Br J Clin Pharmacol; 2021 Oct; 87(10):3863-3870. PubMed ID: 33620754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
    Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
    Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
    Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.